Patient P-02136
Therapy response
Favorable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
71%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S10
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability+9
- Toxicity-6
- Inflammatory activity+3
- Treatment adherence-3
- Nutritional resilience-2
What helped?
- Clinician Review CR-01Day 122Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
69%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- WearableHRV 15 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- WearableSleep 5.4 h, below personal baseline
- Autonomic recovery ↑40
- Wearable2,663 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 16 ms
- Sleep
- 5.6 h
- Steps
- 2,922
- Resting HR
- 73 bpm
Daily log: GI score 62, nutritional resilience 34, adherence 60.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02631 | 52% | S17 | — | — | 58 |
| P-02265 | 46% | S07 | GI-04 | no change | 67 |
| P-02530 | 46% | S07 | — | — | 67 |
| P-02084 | 45% | S11 | GI-04 | no change | 58 |
| P-02334 | 45% | S04 | GI-04 | improved | 66 |
| P-02591 | 44% | S13 | — | — | 68 |
| P-02025 | 43% | S15 | CR-01 | improved | 61 |
| P-02029 | 43% | S18 | — | — | 56 |
| P-02034 | 43% | S18 | — | — | 61 |
| P-02046 | 43% | S10 | — | — | 55 |
| P-02111 | 42% | S20 | — | — | 51 |
| P-02250 | 42% | S04 | — | — | 64 |